MIM
TBPH

MetLife Investment Management’s Theravance Biopharma TBPH Stock Holding History

MetLife Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$392K Buy
23,057
+1,684
+8% +$27.9K ﹤0.01% 2066
2026
Q1 		$347K Sell
21,373
-375
-2% -$6.63K ﹤0.01% 1933
2025
Q4 		$407K Sell
21,748
-2,885
-12% -$47.9K ﹤0.01% 1887
2025
Q3 		$360K Sell
24,633
-2,035
-8% -$25.7K ﹤0.01% 1977
2025
Q2 		$294K Hold
26,668
– – ﹤0.01% 1968
2025
Q1 		$238K Hold
26,668
– – ﹤0.01% 2108
2024
Q4 		$251K Hold
26,668
– – ﹤0.01% 2185
2024
Q3 		$215K Sell
26,668
-897
-3% -$7.77K ﹤0.01% 2250
2024
Q2 		$234K Buy
27,565
+5,549
+25% +$50.1K ﹤0.01% 2146
2024
Q1 		$197K Sell
22,016
-7,562
-26% -$70.1K ﹤0.01% 2212
2023
Q4 		$332K Sell
29,578
-4,364
-13% -$43.9K ﹤0.01% 1932
2023
Q3 		$293K Hold
33,942
– – ﹤0.01% 1975
2023
Q2 		$351K Hold
33,942
– – ﹤0.01% 1924
2023
Q1 		$368K Hold
33,942
– – ﹤0.01% 1839
2022
Q4 		$381K Hold
33,942
– – ﹤0.01% 1820
2022
Q3 		$344K Hold
33,942
– – ﹤0.01% 1901
2022
Q2 		$308K Hold
33,942
– – ﹤0.01% 2005
2022
Q1 		$324K Buy
33,942
+12,090
+55% +$118K ﹤0.01% 2053
2021
Q4 		$241K Buy
21,852
+15,298
+233% +$133K ﹤0.01% 1941
2021
Q3 		$48.5K Sell
6,554
-11,970
-65% -$134K ﹤0.01% 2536
2021
Q2 		$269K Hold
18,524
– – ﹤0.01% 1961
2021
Q1 		$378K Sell
18,524
-2,730
-13% -$51.9K ﹤0.01% 1681
2020
Q4 		$378K Hold
21,254
– – ﹤0.01% 1615
2020
Q3 		$314K Hold
21,254
– – ﹤0.01% 1606
2020
Q2 		$446K Hold
21,254
– – 0.01% 1446
2020
Q1 		$491K Buy
21,254
+1,564
+8% +$39.1K 0.01% 1226
2019
Q4 		$510K Hold
19,690
– – 0.01% 1452
2019
Q3 		$384K Hold
19,690
– – ﹤0.01% 1564
2019
Q2 		$322K Hold
19,690
– – ﹤0.01% 1753
2019
Q1 		$446K Hold
19,690
– – ﹤0.01% 2128
2018
Q4 		$504K Hold
19,690
– – 0.01% 1366
2018
Q3 		$643K Buy
+19,690
New +$537K 0.01% 1372

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

MetLife Investment Management's TBPH Position: Q2 2026 in Review

MetLife Investment Management increased its Theravance Biopharma (TBPH) stake by 7.9% in Q2 2026, buying an estimated $27.9K and bringing the position to 23,057 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #2066.

MetLife Investment Management first reported a position in TBPH in Q3 2018 and has held it in 32 quarters since. The position peaked at $643K in Q3 2018. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • MetLife Investment Management held 23,057 shares of Theravance Biopharma worth $392K as of Q2 2026.
  • MetLife Investment Management bought 1,684 Theravance Biopharma shares in Q2 2026, an estimated $27.9K.
  • Theravance Biopharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2066 holding.
  • MetLife Investment Management first reported a position in Theravance Biopharma in Q3 2018 and has held it in 32 quarters since.
  • MetLife Investment Management's Theravance Biopharma position peaked at $643K in Q3 2018.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.